John Babitt

Handshake
Pharma

Stalled tax reform, high deal prices won't slow pharma M&A pace

Even without U.S. tax reforms expected to spur M&A action, biopharma dealmaking hasn’t slowed down, and nor should industry watchers assume it will.
Carly Helfand Jul 11, 2017 11:18am